Equities Analysts Offer Predictions for Day One Biopharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Stock analysts at HC Wainwright raised their Q3 2024 earnings per share estimates for Day One Biopharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.69) for the quarter, up from their previous estimate of ($0.72). HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($2.74) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $1.24 EPS.

A number of other research firms also recently commented on DAWN. JPMorgan Chase & Co. increased their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. Piper Sandler restated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Finally, Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Day One Biopharmaceuticals Trading Down 3.9 %

NASDAQ:DAWN opened at $16.41 on Thursday. The company has a market capitalization of $1.43 billion, a P/E ratio of -6.89 and a beta of -1.44. The business’s 50-day moving average is $15.46 and its 200 day moving average is $14.19. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently bought and sold shares of DAWN. Summit Rock Advisors LP bought a new stake in Day One Biopharmaceuticals during the 1st quarter valued at $851,000. ProShare Advisors LLC boosted its position in Day One Biopharmaceuticals by 9.1% during the first quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after purchasing an additional 1,447 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Day One Biopharmaceuticals by 67.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 16,817 shares of the company’s stock valued at $278,000 after purchasing an additional 6,750 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after purchasing an additional 1,445 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of Day One Biopharmaceuticals by 89.0% during the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after buying an additional 32,238 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Charles N. York II sold 8,078 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $144,192.30. Following the transaction, the chief financial officer now directly owns 217,293 shares in the company, valued at $3,878,680.05. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Charles N. York II sold 8,078 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $17.85, for a total transaction of $144,192.30. Following the completion of the sale, the chief financial officer now owns 217,293 shares of the company’s stock, valued at approximately $3,878,680.05. The disclosure for this sale can be found here. Insiders have sold a total of 195,247 shares of company stock worth $3,376,817 over the last quarter. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.